The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

Inclusion Criteria: * Body mass index \>28kg/m2 * Age 60-84 years * Established risk factor for developing heart failure, defined as at least one of the following: * hypertension * ischemic heart disease * stroke/transient cerebral ischemia * chronic kidney disease (eGFR 30-45ml/min/1.73m2) Exclusion Criteria: * Diabetes mellitus type 1 or 2 (no medical history, no antidiabetic treatment) * Heart failure with reduced ejection fraction (LVEF \<40%) * Inability to perform exercise test * Dementia * Severe non-compliance * Substance abuse * Severe chronic obstructive pulmonary disease (FEV1\<50% expected value) * Permanent atrial fibrillation * GFR \<30 ml/min/1,73m2 * Severe peripheral artery disease * Cancer treatment within one year beside prostate cancer and basal cell carcinoma * Severe aortic or mitral valve disease * Pregnancy or breastfeeding * Acute hospital admission within 30 days * Participation in other pharmacological study